Seminars in Hematology
Volume 47, Issue 3 , Pages 235-242 , July 2010

Overview of Platelet Transfusion

  • Jeffrey McCullough

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jeffrey McCullough, MD, Department of Laboratory Medicine and Pathology, University of Minnesota, MMC 609, 420 Delaware St SE, Minneapolis, MN 55455

References 

  1. Murphy S, Heaton WA. Rebulla P (Platelet production in the old world and the new). Transfusion. 1996;36:751–754
  2. Whitaker BI, Green J, King MR. The 2007 nationwide Blood Collection and Utilization Survey Report. Washington, DC: Department of Health and Human Services; 2008;
  3. Moroff G, Friedman A, Robkin-Kline L, Gautier G, Luban NLC. Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion. 1984;24:144–146
  4. Filip DJ, Aster RH. Relative hemostatic effectiveness of human platelets stored at 4°C and 22°C. J Lab Clin Med. 1978;91:618–624
  5. Slichter SJ, Harker LA. Preparation and storage of platelet concentrates—II (Storage and variables influence platelet viability and function). Br J Haematol. 1976;34:403–419
  6. Daly PA, Schiffer CA, Aisner J, Wiernik PH. Platelet transfusion therapy: one hour posttransfusion increments are valuable in predicting the need for HLA matched preparations. JAMA. 1980;243:435–438
  7. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905–908
  8. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519–1538
  9. Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med. 1980;31:509–540
  10. Members of the Consensus Development Panel. Platelet transfusion therapy. JAMA. 1987;257:1777–1780
  11. Slichter S, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol. 1978;7:523–529
  12. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870–1875
  13. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant. 1996;18:931–935
  14. Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol. 1997;15:1143–1149
  15. Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601–3606
  16. Aderka D, Praff G, Santo M. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic platelet transfusion policy. Am J Med Sci. 1986;291:147–151
  17. Zumberg MS, del Rosario MLU, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/μL versus 20,000/μL trigger. Biol Blood Marrow Transplant. 2002;8:569–576
  18. Beutler E. Platelet transfusions: the 20,000/mL trigger. Blood. 1993;81:1411–1413
  19. Greeno E, McCullough J, Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion. 2007;47:201–205
  20. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972;287:155–159
  21. Bishop JF, Schiffer CA, Aisner J, Matthews JP, Wiernik PH. Surgery in acute leukemia: a review of 167 operations in thrombocytopenic patients. Am J Hematol. 1987;26:147–155
  22. Platelet transfusion therapy (National Institutes of Health Consensus Conference). Transf Med Rev. 1987;195–200
  23. Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus conference on platelet transfusion (Royal College of Physicians of Edinburgh, November 27-28, 1997). Br J Haematol. 1998;101:609–617
  24. Edelson RN, Chernik NL, Posner JB. Spinal subdural hematomas complicating lumbar puncture. Arch Neurol. 1974;31:134–137
  25. Breuer AC, Tyler R, Marzewski DJ, et al. Radicular vessels are the most probable source of needle induced blood in lumbar puncture. Cancer. 1982;49:2168–2172
  26. Howard SC, Gajjar A, Ribeiro RC, et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA. 2000;284:2222–2224
  27. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol. 1990;94:747–753
  28. Chu DZJ, Shivshanker K, Stroehlein JR, et al. Thrombocytopenia and gastrointestinal hemorrhage in the cancer patient: prevalence of unmasked lesions. Gastrointest Endosc. 1983;29:269–272
  29. Weiss SM, Hert RC, Gianola FJ, et al. Complications of fiberoptic bronchoscopy in thrombocytopenic patients. Chest. 1993;104:1025–1028
  30. Papin TA, Lynch JP, Weg JG. Transbronchial biopsy in the thrombocytopenic patient. Chest. 1985;88:549–552
  31. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008
  32. Aster RH, Jandl JH. Platelet sequestration in man. II (Immunological and clinical studies). J Clin Invest. 1964;43:856
  33. Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med. 1986;104:808–809
  34. Murray DJ, Pennell BJ, Weinstein SL, Olson JD. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg. 1995;80:336–342
  35. Murray DJ, Olson J, Strauss R, Tinker JH. Coagulation changes during packed red bell replacement of major blood loss. Anesthesiology. 1988;69:839–845
  36. Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement: a study of 172 cases. Vox Sang. 1982;42:113
  37. Counts RB, Haisch C, Simon TL, Maxwell NG, Heimbach DM, Carrico CJ. Hemostasis in massively transfused trauma patients. Ann Surg. 1979;190–191
  38. Holcomb JB, Hess JR. Early massive trauma transfusion: state of the art. J Trauma. 2006;60:S1–S2
  39. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg. 1984;37:359–364
  40. Goodnough LT, Johnston MF, Ramsey G, et al. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting (Transfusion Practices Committee of the American Association of Blood Banks). Ann Thorac Surg. 1990;50:675–683
  41. Hersh JK, Hom EG, Brecher ME. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient. Transfusion. 1998;38:637–644
  42. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy normal apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001;98:1346–1351
  43. Klumpp TR, Herman JH, Gaughan JP, et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion. 1999;39:674–681
  44. Cid J, Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion. 2007;47:464–470
  45. Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood. 2009;113:1564–1573
  46. Slichter J, Kaufman R, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage (the PLADO trial). N Engl J Med. 2010;362:600–613
  47. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood. 1965;26:732–743
  48. Duquesnoy RJ, Anderson AJ, Tomasulo PA, Aster RH. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood. 1979;54:595–599
  49. Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion: results of a randomized trial. Transfusion. 1989;29:384–389
  50. Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood. 1987;709:23–30
  51. Goldfinger D, McGinnis MA. Rh incompatible platelet transfusions-risks and consequences of sensitizing immunosuppressed patients. N Engl J Med. 1971;284:942–944
  52. Cid J, Ortin X, Elies E, et al. Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion. 2002;42:173–176
  53. Slichter SJ, Davis K, Enright H, et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106–4114
  54. Aster RJ, Jandl JH. Platelet sequestration in man. II (Immunological and clinical studies). J Clin Invest. 1964;43:856–869
  55. Bishop JF, McGrath K, Wolf MM, et al. Clincal factors influencing the efficacy of pooled platelet transfusions. Blood. 1988;71:383–387
  56. Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang. 1994;66:200–205
  57. Yankee RA, Graff KS, Dowling R, Henderson ES. Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med. 1973;288:760–764
  58. Duquesnoy RJ, Filip DJ, Rodey GE, et al. Successful transfusion of platelets “mismatched” for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol. 1977;2:219–223
  59. Lohrman HP, Bull MI, Decter JA, et al. Platelet transfusions from HLA compatible unrelated donors to alloimmunized patients. Ann Intern Med. 1974;80:9–14
  60. Moroff G, Garratty G, Heal JM, et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion. 1992;32:633–640
  61. Rachel JM, Sinor LT, Tawfik OW, et al. A solid-phase red cell adherence test for platelet cross-matching. Med Lab Sci. 1985;42:194–195
  62. Rachel JM, Summers TC, Sinor LT, Plapp FV. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol. 1988;90:63–68
  63. O'Connell BA, Lee EJ, Rothko K, Hussein MA, Schiffer CA. Selection of histocompatibility apheresis platelet donors by cross-matching random donor platelet concentrates. Blood. 1992;79:527–531
  64. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood. 1993;81:3428–3434
  65. Class FHJ, Smeenk RJT, Schmidt R, et al. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol. 1981;9:84–89
  66. Seftel MD, Growe GH, Petraszko T. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004;103:333–339
  67. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861–1869
  68. Semple JW, Freedman J. Recipient antigen-processing pathways of allogeneic platelet antigens: essential mediators of immunity. Transfusion. 2002;42:958–961
  69. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988;71:1402–1407
  70. Saarinen UM, Kekomaki R, Siimes MA, Myllylai G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood. 1990;75:512–517
  71. van Marwijk Kooy M, van Prooijen HC, Moes M, et al. Use of leukocyte depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood. 1991;77:201–205
  72. Heddle NM, Blajchman MA. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood. 1995;85:603–606

PII: S0037-1963(10)00057-0

doi: 10.1053/j.seminhematol.2010.04.001

Seminars in Hematology
Volume 47, Issue 3 , Pages 235-242 , July 2010

Article Tools